Astra and Daiichi bag FDA approval based on Destiny-Breast09.

The new phase 3 trial, in first-line CLL, is expected to begin in January 2026. 

Two new PD-(L)1 x VEGF projects have entered the clinic.

On a cross-trial basis varegacestat beats Ogsiveo.

But the Japanese group is focused on biliary tract cancer rather than glioblastoma.

No fewer than four ADCs with this target start human testing.

The company is set to start a phase 2/3 trial this month. 

Arcus steps back from TIGIT as its Fc-silent claim crumbles.

Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.

Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.